465 related articles for article (PubMed ID: 23339826)
1. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
[TBL] [Abstract][Full Text] [Related]
3. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
[TBL] [Abstract][Full Text] [Related]
4. [Use of an implantable defibrillator for the prevention of sudden death in hypertrophic cardiomyopathy].
Hentati M; Ben Ameur I; Kechida Z; Charfeddine H; Hached L; Grati Z; Kammoun S
Tunis Med; 2003; 81 Suppl 8():675-9. PubMed ID: 14608758
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of the risk of sudden death in hypertrophic cardiomyopathy].
Sadoul N; de Chillou C; Aliot E; McKenna WJ
Arch Mal Coeur Vaiss; 1999 Apr; 92 Spec No 1():65-73. PubMed ID: 10326160
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of new predictive scores for sudden cardiac death in childhood hypertrophic cardiomyopathy in a French cohort.
Fontanges PA; Marquie C; Houeijeh A; Baudelet JB; Richard A; Amenyah C; Lucidarme S; Bonnet M; Delarue A; Bichali S; Assi NA; Marechaux S; Menet A; Vaksmann G; Godart F; Domanski O
Arch Cardiovasc Dis; 2024; 117(6-7):402-408. PubMed ID: 38821762
[TBL] [Abstract][Full Text] [Related]
7. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy.
Elliott PM; Gimeno Blanes JR; Mahon NG; Poloniecki JD; McKenna WJ
Lancet; 2001 Feb; 357(9254):420-4. PubMed ID: 11273061
[TBL] [Abstract][Full Text] [Related]
8. Improving sudden cardiac death risk stratification in hypertrophic cardiomyopathy using established clinical variables and genetic information.
Amr A; Koelemen J; Reich C; Sedaghat-Hamedani F; Kayvanpour E; Haas J; Frese K; Lehmann D; Katus HA; Frey N; Meder B
Clin Res Cardiol; 2024 May; 113(5):728-736. PubMed ID: 37792019
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Begley DA; Mohiddin SA; Tripodi D; Winkler JB; Fananapazir L
Pacing Clin Electrophysiol; 2003 Sep; 26(9):1887-96. PubMed ID: 12930505
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis.
Kazmirczak F; Chen KA; Adabag S; von Wald L; Roukoz H; Benditt DG; Okasha O; Farzaneh-Far A; Markowitz J; Nijjar PS; Velangi PS; Bhargava M; Perlman D; Duval S; Akçakaya M; Shenoy C
Circ Arrhythm Electrophysiol; 2019 Sep; 12(9):e007488. PubMed ID: 31431050
[TBL] [Abstract][Full Text] [Related]
11. Current perspectives of sudden cardiac death management in hypertrophic cardiomyopathy.
Pu L; Li J; Qi W; Zhang J; Chen H; Tang Z; Han Y; Wang J; Chen Y
Heart Fail Rev; 2024 Mar; 29(2):395-404. PubMed ID: 37865929
[TBL] [Abstract][Full Text] [Related]
12. High T2-weighted signal intensity for risk prediction of sudden cardiac death in hypertrophic cardiomyopathy.
Gommans DHF; Cramer GE; Bakker J; Dieker HJ; Michels M; Fouraux MA; Marcelis CLM; Verheugt FWA; Timmermans J; Brouwer MA; Kofflard MJM
Int J Cardiovasc Imaging; 2018 Jan; 34(1):113-120. PubMed ID: 29063221
[TBL] [Abstract][Full Text] [Related]
13. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients.
Monserrat L; Elliott PM; Gimeno JR; Sharma S; Penas-Lado M; McKenna WJ
J Am Coll Cardiol; 2003 Sep; 42(5):873-9. PubMed ID: 12957435
[TBL] [Abstract][Full Text] [Related]
14. 3D speckle tracking echocardiographic strain pattern in Hypertrophic Cardiomyopathy and its relation with Sudden Cardiac Death risk markers.
Rakesh K; Rajesh GN; Vellani H
Indian Heart J; 2021; 73(4):451-457. PubMed ID: 34474757
[TBL] [Abstract][Full Text] [Related]
15. Effect of beta-blockers and exercise restriction on the prevention of sudden cardiac death in pediatric hypertrophic cardiomyopathy.
Ito Y; Sakaguchi H; Tsuda E; Kurosaki K
J Cardiol; 2024 Jun; 83(6):407-414. PubMed ID: 38043708
[TBL] [Abstract][Full Text] [Related]
16. Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy.
Maron BJ
Cardiol Rev; 2002; 10(3):173-81. PubMed ID: 12047795
[TBL] [Abstract][Full Text] [Related]
17. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
; Ommen SR; Ho CY; Asif IM; Balaji S; Burke MA; Day SM; Dearani JA; Epps KC; Evanovich L; Ferrari VA; Joglar JA; Khan SS; Kim JJ; Kittleson MM; Krittanawong C; Martinez MW; Mital S; Naidu SS; Saberi S; Semsarian C; Times S; Waldman CB
J Am Coll Cardiol; 2024 Jun; 83(23):2324-2405. PubMed ID: 38727647
[TBL] [Abstract][Full Text] [Related]
18. Head-to-Head Comparison and Temporal Trends of Cardiac MRI Recommendations in ESC versus ACC/AHA Guidelines: A Systematic Review and Meta-Analysis.
Ciocca N; Lu H; Tzimas G; Muller O; Masi A; Maurizi N; Skalidis I; Gissler MC; Monney P; Schwitter J; Ge Y; Antiochos P
Radiol Cardiothorac Imaging; 2024 Jun; 6(3):e230271. PubMed ID: 38842455
[TBL] [Abstract][Full Text] [Related]
19. Candidacy and long-term outcomes of subcutaneous implantable cardioverter-defibrillators in current practice in patients with hypertrophic cardiomyopathy.
Rella V; Maurizi N; Bernardini A; Brasca FM; Salerno S; Meda M; Mariani D; Torchio M; Ravaro S; Cerea P; Castelletti S; Fumagalli C; Conte G; Auricchio A; Girolami F; Pieragnoli P; Carrassa GM; Parati G; Olivotto I; Perego GB; Cecchi F; Crotti L
Int J Cardiol; 2024 Aug; 409():132202. PubMed ID: 38795975
[TBL] [Abstract][Full Text] [Related]
20. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator.
Primo J; Geelen P; Brugada J; Filho AL; Mont L; Wellens F; Valentino M; Brugada P
J Am Coll Cardiol; 1998 Apr; 31(5):1081-5. PubMed ID: 9562010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
